NEWSASIA Bringing you all the latest News from the Science Industry
Labcyte Signs Bioscreen Instruments as Exclusive Distributor in India
Labcyte, the developer of acoustic liquid transfer, has announced the selection of Bioscreen Instruments Pvt Ltd as its exclusive distributor in India.
“Bioscreen is a leading distributor in India. They will be a great partner for us,” said Stephen Bates, Sr. Vice President of Sales, Marketing and Service of Labcyte Inc. “As we continue to expand throughout Asia, Bioscreen will help us further broaden our existing user base in the pharmaceutical industry and the contract research organisations (CROs) that service them, Bioscreen will provide them with industry-leading Labcyte acoustic technology for compound management, high-throughput and secondary screening. Bioscreen will give our new customers in India immediate support and interaction.
“Bioscreen will also introduce us to new users in the
growing genomics market. We feel that with the Labcyte platforms, Bioscreen can meet the genomics customers’ needs for miniaturisation, precision and accuracy while remaining contamination-free.”
“We are extremely pleased to be the Labcyte partner in India. It is a great recognition of our distributor capabilities across the entire country of India. Labcyte products will allow us to provide our customers with state-of-the-art platform technology so that they can excel in their efforts,” said Mr. S. Radha Krishnan, Managing Director of Bioscreen Instruments. “We see a great potential market for low-volume liquid handlers in India. We believe that the miniaturisation capabilities provided by Labcyte technology will be especially useful for the growing genomics markets, especially for gene expression, SNP analysis and RNAi.”
TO FIND OUT MORE CIRCLE NO. 306 Agilent Technologies Announces First
Microarray Certified Service Provider in Korea Agilent Technologies Inc has announced that DNA Link, Inc has achieved Certified Service Provider status for Agilent microarray platform. Certification is for array-based comparative genomic hybridisation (aCGH) and microRNA (miRNA) applications, both representing fast growing segments for the Agilent genomics business.
aCGH measures chromosomal duplications and deletions, while miRNA is a recently-discovered class of small non-coding RNAs estimated to regulate about 30% of all human genes. Both are implicated in regulating gene expression and function in relating to human diseases. Most recently, an international team led by researchers at Seoul National University had published a breakthrough study using custom- designed Agilent CGH array to sequence the entire gene map of a Korean male.
“DNA Link is the first Agilent Certified Service Provider in Korea. It has established facility and well-trained staff to support our expanding applications and customer base in Korea,” said Dr. Chris Tan, Agilent Director of Sales, Genomics and Life Sciences, Asia Pacific and Japan. “This is a critical milestone for us in this strategically important market in Asia Pacific. Through this partnership with DNA Link and its close network with academic universities and government
institutions, Agilent is in the best position to provide incomparable service to the customers in Korea with high quality genomic solutions”
DNA Link is an emerging leader in medical genetics research with strong alliances with major laboratories. Under this partnership, DNA Link will be able to offer a full portfolio of applications backed with high quality array data from Agilent. The establishment of aCGH technology, in particular will enable DNA Link to best service the medical genetics / cytogenetic community in Korea.
“We’re pleased to add Agilent microarray platform in our service portfolio,” said Jong-Eun Lee, PhD, CEO of DNA Link, Inc. “Agilent’s cytogenetic tools is going to be a main focus area for us and the flexibility that the platform supports offers unlimited possibilities for researchers in Korea.”
TO FIND OUT MORE CIRCLE NO. 308
by Gwyneth Astles
NEWSASIA NEWSASIA NEWSASIA NEWSASIA
IKA® India Plant with
Manufacturing, Service and Sales Facilities
IKA®
Group Germany, a global market leader for laboratory equipment, analytical and process technology, have opened a new Indian subsidiary at Bangalore. IKA®
’s local site has manufacturing on over
2 000 square meters and is furnished with testing machines, a selected pool of trial units and a spare part depot. The application centre provides customer - service and after-sales support with both German and Indian consultants and engineers.
IKA®
India are offering laboratory and analysing instruments including, machines and plants for food, pharma, cosmetic and chemical applications.
TO FIND OUT MORE CIRCLE NO. 307
Milestone Order Pharmaceutical Freeze Drying Equipment
GEA Lyophil, part of GEA Pharma Systems, has won a milestone order from the Zheiiang Hisun Pharmaceutical Co. Ltd in Taizhou Zheiiang, China for the supply of pharmaceutical freeze dryers with automatic load and unload systems (ALUS). The order is a major breakthrough in the region allowing Hisun to expand its operations into formulated pharmaceutical products for injection focus in oncology and infective diseases.
GEA Lyophil GmbH will supply seven freeze drying systems and five ALUS systems with a total value in excess of 15 million Euro. The equipment will be used at the new facilities in the Fuyang pharmaceutical valley and will allow Hisun to focus on the production of anti-tumour, anti-infective, general biologics and anti-TB product for both the domestic and export markets. Hisun is planning to invest over 100 million euro in the Fuyang facility making it one of the biggest pharmaceutical production sites in China.
The Chinese pharmaceutical industry is investing heavily in top quality production technology both for domestic and export pharmaceuticals. This recent order for GEA Lyophil is a clear illustration of this trend.
TO FIND OUT MORE CIRCLE NO. 309
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144
